{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-031337","form_type":"8-K","ticker":"PEPG","cik":"0001835597","company_name":"PepGen Inc.","filed_at":"2025-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.175501+00:00","generated_at":"2026-05-25T15:15:00.145073+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"PepGen voluntarily pauses Phase 2 CONNECT2-EDO51 study; awaits 10 mg/kg data from CONNECT1","bullets":["Temporarily pauses CONNECT2-EDO51 in DMD until review of 10 mg/kg data from ongoing CONNECT1-EDO51 study.","No new safety issues observed in PGN-EDO51 program since safety update on January 23, 2025.","CONNECT1 10 mg/kg cohort fully enrolled; data expected in third quarter of 2025.","Resources focused on completing CONNECT1 and advancing FREEDOM-DM1 studies in myotonic dystrophy type 1.","CEO states pause allows gathering additional safety data and potential improvement of CONNECT2 design."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-031337","json":"https://secwatch.observer/filing/0000950170-25-031337.json","markdown":"https://secwatch.observer/filing/0000950170-25-031337.md","text":"https://secwatch.observer/filing/0000950170-25-031337.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835597/000095017025031337/0000950170-25-031337-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835597/000095017025031337/pepg-20250304.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T15:15:00.145073+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}